News

Initial clinical data on Medigene's DC vaccines to be presented at the SITC Conference

Martinsried/Munich, 7 November, 2014. Medigene AG (MDG1, Frankfurt, Prime Standard) announces that two presentations on its antigen-tailored dendritic cell (DC) vaccines and its T cell receptor- (TCR) modified T cells will be presented at SITC (Society for Immunotherapy of Cancer) 29th Annual Meeting & Associated Programs in National Harbor/Washington D.C., USA, on Saturday, 8 November 2014.

The poster entitled "Next generation dendritc cells for immunotherapy of acute myeloid leukemia" shows initial clinical data collected in a current investigator initiated phase I/II clinical trial for the treatment of acute myeloid leukemia (AML) conducted at the Ludwig-Maximilian University Hospital Großhadern, Munich, in cooperation with Prof. Marion Subklewe and Prof. Wolfgang Hiddemann. 

The abstract is available for download at:
www.immunotherapyofcancer.org/content/pdf/2051-1426-2-S3-P84.pdf

The poster entitled "Generation of tumour antigen-specific CD4+ and CD8+ T cells by simultaneous MHC-I and -II epitope presentation in vitro and in vivo" outlines parts of Medigene's immunotherapeutic TCR program, particularly the isolation and identification of tumour specific T cells.

The abstract is available for download at: www.immunotherapyofcancer.org/content/pdf/2051-1426-1-S1-P6.pdf

About Medigene's DC vaccines: The platform for the development of antigen-tailored DC vaccines is the most advanced platform of the three highly innovative and complementary immunotherapy platforms of Medigene Immunotherapies GmbH (formerly Trianta Immunotherapies GmbH), which was recently acquired by Medigene AG. Currently the DC vaccines are being evaluated in two ongoing investigator-initiated trials in clinical phases II (prostate cancer) and I/II (AML, acute myeloid leukaemia). Medigene concentrates on the further development of DC vaccines in hematological malignancies and plans to initiate a further clinical study in AML in 2014.

Medigene's dendritic cell product platform allows the design of new generation dendritic cell vaccines. Dendritic cells can take up antigens efficiently, process them and present them on their surface in a form that can induce T cells to divide and mature and thus enable the T cells to attack tumour cells. Dendritic cells can also induce natural killer cells to become active and attack tumour cells. Medigene has established new, fast and efficient methods for preparation of autologous (patient-specific) mature dendritic cells that have relevant characteristics to activate both T cells and natural killer cells. They are developed to carry multiple tumour antigens to treat various types of cancer, suited for treatment of minimal residual disease or use in combination therapies.

About Medigene's T cell receptor- (TCR) modified T cells: This therapy approach aims to utilize the body's own machinery - the T cell - to target and destroy cancer by arming normal patient-derived T cells with new T cell receptors that enable them to detect and efficiently kill tumour cells. This form of immunotherapy is designed to overcome a patient's tolerance to cancer since the T cells of the patient are activated and modified outside the body, away from generalized immune suppression in the patient. Compared to small molecule or antibody based therapies this approach can be used for new targets to fight tumours. A large army of specific T cells is made available to patients within a short period of time. The therapy is potentially suited for the treatment of advanced cancer.

Currently, a comprehensive library of recombinant T-cell receptors and a GMP-compliant process for their combination with patient-derived T cells is being established. Discussions with regulatory authorities for the preparation of first clinical trials with defined product candidates are ongoing.

Medigene AG
is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. Medigene concentrates on the development of personalized T cell immunotherapies with a focus on haematological malignancies. Medigene is the first German biotech company to have revenues from a marketed product, which is distributed by commercial partner companies. Medigene has advanced drug candidates which are licensed to partners and additional candidates in clinical development. The company is developing highly innovative treatment platforms concentrating on cancer and autoimmune diseases. For more information, please visit www.medigene.com.

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. These trademark may be owned or licensed in select locations only.

Contact Medigene
Julia Hofmann, Anja Clausnitzer
Tel.: +49 - 89 - 20 00 33 - 33 01
Email: investor@medigene.com

To unsubscribe from the press release distribution list, please visit: www.medigene.de/unsubscribe